Chronic Kidney Disease (CKD) Diagnosis, Staging, Referral, and Management Guidelines

Diagnosis & Staging

CKD is diagnosed when either kidney damage (albumin‑to‑creatinine ratio > 30 mg/g) or an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m² persists for ≥ 3 months【1】【2】.
Stage 3 CKD is defined by an eGFR of 30–59 mL/min/1.73 m², indicating loss of roughly half of normal adult kidney function【2】【3】.
When eGFR falls below 60 mL/min/1.73 m², the prevalence of CKD‑related complications (hypertension, anemia, malnutrition, bone disease) rises markedly【1】.
End‑stage renal disease (ESRD) is defined as an eGFR < 15 mL/min/1.73 m² or the need for dialysis or kidney transplantation【2】【3】.
An albumin‑to‑creatinine ratio > 30 mg/g confirms kidney damage and fulfills the CKD diagnostic criterion【1】.

Referral to Nephrology

Nephrology consultation should be initiated when a patient’s eGFR declines below 30 mL/min/1.73 m² (CKD stage 4)【4】【5】.
Early referral enables timely preparation for kidney replacement therapy, management of complex complications (anemia, secondary hyperparathyroidism, resistant hypertension, electrolyte disturbances), and discussion of dialysis or transplant options【4】【5】【6】【7】.
Late referral (shortly before dialysis) is associated with higher post‑dialysis mortality【4】.

CKD‑Related Cardiovascular Risk

Patients with CKD are far more likely to die from cardiovascular disease (CVD) than to progress to ESRD【1】【8】.
CVD events occur more frequently than kidney failure in the CKD population【1】.
CKD places individuals in the highest risk tier for subsequent CVD events【1】.
Early‑stage CKD (stages 1‑4) is > 100‑fold more prevalent than kidney failure (stage 5)【2】.
Reduced GFR in older adults independently predicts mortality and CVD, beyond normal aging effects【1】【2】.

Hypertension Management in Diabetic CKD

In adults with type 1 or type 2 diabetes and CKD (eGFR < 60 mL/min/1.73 m², albuminuria ≥ 300 mg/g), initiating an ACE inhibitor or an ARB reduces the risk of progression to ESRD【6】【5】.
Blood pressure targets of < 140/90 mmHg are recommended to lower CVD mortality and slow CKD progression; lower targets (< 130/80 mmHg) are advisable when albuminuria is ≥ 300 mg/g【6】.
Combined ACE‑inhibitor + ARB therapy should be avoided because it raises the risk of hyperkalemia and acute kidney injury without providing additional CVD or CKD benefit【6】【7】【5】.
ACE inhibitors or ARBs are not indicated for CKD prevention in patients without hypertension【7】.

Definitions: Kidney Failure vs. ESRD

Kidney failure is defined as either an eGFR < 15 mL/min/1.73 m² (usually with uremic signs) or the initiation of kidney replacement therapy【2】【3】.
Approximately 98 % of kidney‑failure patients in the United States start dialysis when eGFR falls below 15 mL/min/1.73 m²【2】.
ESRD is an administrative classification denoting patients who are receiving dialysis or have undergone transplantation (the basis for Medicare ESRD coverage)【2】【3】.
ESRD does not include kidney‑failure patients who are not on dialysis or transplantation【2】.
The term “kidney failure with replacement therapy (KFRT)” is now preferred for epidemiologic studies to encompass both dialysis and transplant recipients【9】.

Antiplatelet Therapy in ESRD

Low‑dose aspirin (75–162 mg daily) may be considered for primary prevention of ischemic vascular events in ESRD patients if the bleeding risk is low【10】.
Evidence is limited; however, meta‑analyses of dialysis‑access studies show a significant reduction in serious vascular events with antiplatelet therapy (mainly aspirin)【10】.
Patients with CKD/ESRD have a 10‑ to 100‑fold increased risk of vascular disease, underscoring the potential benefit of antiplatelet agents when bleeding risk is acceptable【10】.
For secondary prevention, antiplatelet therapy is recommended in CKD patients with established cardiovascular disease【10】.

Statin Therapy in CKD

In adults with type 2 diabetes and CKD stages 1‑4, statin therapy is recommended regardless of calculated cardiovascular risk score to reduce CVD risk【11】.
Cardiovascular disease is the leading cause of death in individuals with CKD【11】.
The SHARP trial demonstrated that LDL‑C lowering with a statin + ezetimibe combination reduces major adverse cardiovascular events in moderate‑to‑severe CKD, especially when baseline LDL‑C is high【11】.
Statin initiation should be independent of other risk factors to prevent CVD outcomes in early‑to‑moderate CKD【11】.
Renal‑clearance considerations: pitavastatin, pravastatin, and rosuvastatin have partial kidney clearance; atorvastatin, fluvastatin, lovastatin, and simvastatin are hepatically cleared【11】. Dose adjustments are required for all statins except atorvastatin and fluvastatin in CKD【11】.
Statins have not shown benefit in dialysis patients (4D and AURORA trials); therefore, initiation is not recommended once a patient is on dialysis【11】.

Guideline Recommendations for Managing Stage III Chronic Kidney Disease with Air‑Pollution Exposure

Pharmacologic Management

SGLT2‑inhibitor therapy is recommended for patients with both diabetes and stage III CKD (eGFR 30‑59 mL/min/1.73 m²) to reduce renal disease progression and cardiovascular events. The recommendation follows KDIGO guidance and is supported by high‑quality randomized trial evidence. 12

Environmental Exposure Recommendations

Implement indoor‑air quality measures—such as adequate ventilation when using gas‑powered cooking appliances—to reduce NO₂ exposure, which can exceed outdoor concentrations. This recommendation is based on epidemiologic data linking indoor combustion sources to kidney‑injurious pollutants. Evidence is moderate (observational cohort). 13
Advise patients with stage III CKD to limit outdoor activities on days with high ambient pollution levels. The guidance targets individuals who have already lost roughly 50 % of normal kidney function and are at heightened risk for complications. Evidence is moderate (prospective cohort). 14

Risk Assessment and Monitoring

Systematically assess traditional CKD risk factors—diabetes, hypertension, and established cardiovascular disease—when evaluating patients with air‑pollution exposure. This aligns with standard CKD risk‑stratification practices and is supported by strong epidemiologic evidence. 15

Environmental and Socio‑Economic Context

Recognize that extreme climate conditions (heat waves and severe cold) increase mortality risk in CKD patients, adding to the burden of air‑pollution exposure. The statement reflects moderate‑strength evidence from population‑based analyses. 16
Prioritize CKD screening in high‑risk groups, including individuals residing in areas with elevated air‑pollution levels, because CKD often remains undiagnosed until later stages when interventions are less effective. Evidence is moderate (observational studies). 16
Address health‑equity concerns: populations with limited resources and poor healthcare access experience the greatest risk of kidney‑disease complications related to air‑pollution exposure. This recommendation is grounded in moderate‑strength evidence highlighting socioeconomic disparities. 16

Management of Volume Overload and Cardiovascular Risk in CKD with Preserved Ejection Fraction

Renal Sodium Handling and Volume Overload

In chronic kidney disease, impaired renal sodium excretion creates a positive sodium balance that expands extracellular volume, contributing to anasarca and dyspnea. 17

Diuretic Therapy in Advanced CKD

Loop diuretics become less effective in advanced CKD because reduced delivery to the tubular lumen limits natriuresis; adding a thiazide‑type diuretic (e.g., metolazone) is often required to achieve adequate edema control. 17

Diagnosis of HFpEF in CKD

Patients with preserved ejection fraction can still have heart failure; diastolic dysfunction with elevated cardiac filling pressures leads to pulmonary congestion and exertional dyspnea. 18
Diagnostic criteria for HFpEF include natriuretic peptide thresholds (BNP > 35 pg/mL in ambulatory settings or > 100 pg/mL when hospitalized) together with structural or functional cardiac abnormalities. 18

Diabetes Mellitus Impact on CKD and Volume Overload

Diabetes mellitus raises the risk of developing CKD by ~30% and is associated with a higher incidence of volume‑overload complications in patients with CKD. 19

Renin‑Angiotensin‑Aldosterone System (RAAS) Inhibition

ACE inhibitors or ARBs are recommended for individuals with a urinary albumin‑to‑creatinine ratio ≥30 mg/g to slow CKD progression, although they may cause a transient rise in serum creatinine. 19
When prescribing ACE inhibitors or ARBs to CKD patients, serum creatinine and potassium should be monitored regularly to detect adverse changes. [20][19]

Monitoring and Referral Recommendations

Nephrology referral is advised when estimated glomerular filtration rate falls below 30 mL/min/1.73 m² to facilitate timely preparation for complications related to CKD and volume overload. 19